Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives

Objective To compare uptake in the ordering of biosimilars at a Veterans Affairs Medical Center (VAMC) to that at an academic medical center, where institutional incentives for infused medications differ. Methods We performed a cross‐sectional study of medical record data and estimated institutional...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2020-07, Vol.72 (7), p.1067-1071
Main Authors: Baker, Joshua F., Leonard, Charles E., Lo Re, Vincent, Weisman, Michael H., George, Michael D., Kay, Jonathan
Format: Article
Language:English
Subjects:
Biological products
Cost control
Costs
Government programs
Health care facilities
Incentives
Infliximab
Monetary incentives
Monoclonal antibodies
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To compare uptake in the ordering of biosimilars at a Veterans Affairs Medical Center (VAMC) to that at an academic medical center, where institutional incentives for infused medications differ. Methods We performed a cross‐sectional study of medical record data and estimated institutional financial incentives at 2 medical centers in Philadelphia: 1) the University of Pennsylvania Health System (UPHS), and 2) the local VAMC. All ordering events for filgrastim or infliximab products were quantified over time and stratified according to product (biosimilar versus reference product) and center. Financial incentives to the institutions over time were determined based on actual drug costs for the VAMC and average sales prices (ASPs) and Medicare Part B reimbursement rates for UPHS. Results There were 15,761 infusions of infliximab at UPHS, of which 99% were for the reference product. There was a sharper decline in the use of reference products at the VAMC; 62% of the 446 infliximab infusions ordered at the VAMC were for the reference product. ASPs were consistently lower for biosimilar infliximab products, but the estimated institutional financial incentives remained similar over time for biosimilar and reference infliximab at UPHS. At the VAMC, the costs for 100‐mg vials of reference infliximab and infliximab‐abda were $623.48 and $115.58, respectively: a $507.90 (81%) savings per vial. Conclusion The uptake of infliximab biosimilars has been slow at an academic medical center compared to a nearby VAMC, where financial savings are realized by the institution from its use. Slow adoption of biosimilar medications may impact the rates of decline in costs.
ISSN:2326-5191
2326-5205
DOI:10.1002/art.41277